Clinical trials: CV Risk
Type 2 Diabetes Mellitus, CV Risk
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
- Trial name
- NCT00648284
- Volunteers
- 1,100 people
- Sponsor
- GlaxoSmithKline